107 related articles for article (PubMed ID: 34237209)
1. Clinicopathologic Characteristics and Clinical Outcome of Localized Liposarcoma: A Single-Center Experience over 25 Years and Evaluation of PD-L1 Expression.
Chae H; Kim JE; Kim W; Lee JS; Song SY; Lee MH; Chung HW; Cho KJ; Song JS; Ahn JH
Cancer Res Treat; 2022 Apr; 54(2):579-589. PubMed ID: 34237209
[TBL] [Abstract][Full Text] [Related]
2. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma.
Singer S; Antonescu CR; Riedel E; Brennan MF
Ann Surg; 2003 Sep; 238(3):358-70; discussion 370-1. PubMed ID: 14501502
[TBL] [Abstract][Full Text] [Related]
3. The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions.
Lee K; Song JS; Kim JE; Kim W; Song SY; Lee MH; Chung HW; Cho KJ; Lee JS; Ahn JH
Eur J Surg Oncol; 2020 Jul; 46(7):1287-1293. PubMed ID: 32127249
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of prognostic factors for liposarcoma].
Zhang Q; Li JM; Liu JL; Wei YZ
Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):943-948. PubMed ID: 31874553
[No Abstract] [Full Text] [Related]
5. Liposarcoma: Clinico-pathological analysis, prognostic factors and survival in a series of 307 patients treated at a single institution.
Muratori F; Frenos F; Bettini L; Matera D; Mondanelli N; Scorianz M; Cuomo P; Scoccianti G; Beltrami G; Greto D; Livi L; Baldi G; Roselli G; Capanna R; Campanacci DA
J Orthop Sci; 2018 Nov; 23(6):1038-1044. PubMed ID: 30007495
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
Zhu J; Wen H; Bi R; Wu Y; Wu X
J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
[TBL] [Abstract][Full Text] [Related]
7. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
8. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
9. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
[TBL] [Abstract][Full Text] [Related]
10. Influence of age and subtype in outcome of operable liposarcoma.
Greto D; Saieva C; Loi M; Terziani F; Visani L; Garlatti P; Lo Russo M; Muntoni C; Becherini C; Topulli J; Campanacci D; Beltrami G; Scoccianti G; Muratori F; Bonomo P; Desideri I; Francolini G; Livi L
Radiol Med; 2019 Apr; 124(4):290-300. PubMed ID: 30421387
[TBL] [Abstract][Full Text] [Related]
11. Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma.
Miyake M; Oda Y; Nishimura N; Morizawa Y; Ohnishi S; Hatakeyama K; Fujii T; Hori S; Gotoh D; Nakai Y; Anai S; Torimoto K; Tsukamoto S; Fujii H; Kido A; Honoki K; Matsumura Y; Okajima E; Tanaka N; Fujimoto K
Oncol Lett; 2020 Nov; 20(5):190. PubMed ID: 32952659
[TBL] [Abstract][Full Text] [Related]
12. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
[TBL] [Abstract][Full Text] [Related]
13. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
14. Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
Girolami I; Pantanowitz L; Mete O; Brunelli M; Marletta S; Colato C; Trimboli P; Crescenzi A; Bongiovanni M; Barbareschi M; Eccher A
Endocr Pathol; 2020 Sep; 31(3):291-300. PubMed ID: 32468210
[TBL] [Abstract][Full Text] [Related]
15. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.
Hulsbergen AFC; Mammi M; Nagtegaal SHJ; Lak AM; Kavouridis V; Smith TR; Iorgulescu JB; Mekary RA; Verhoeff JJC; Broekman MLD; Phillips JG
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):258-267. PubMed ID: 32335185
[TBL] [Abstract][Full Text] [Related]
18. Histologic Subtype Defines the Risk and Kinetics of Recurrence and Death for Primary Extremity/Truncal Liposarcoma.
Bartlett EK; Curtin CE; Seier K; Qin LX; Hameed M; Yoon SS; Crago AM; Brennan MF; Singer S
Ann Surg; 2021 Jun; 273(6):1189-1196. PubMed ID: 31283560
[TBL] [Abstract][Full Text] [Related]
19. Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery.
Keung EZ; Hornick JL; Bertagnolli MM; Baldini EH; Raut CP
J Am Coll Surg; 2014 Feb; 218(2):206-17. PubMed ID: 24315890
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]